9 February 2022 in Journal of Vascular and Interventional Radiology
6 April 2015 in Clinical Imaging
4 July 2020 in Journal of American College Health
Our pilot study tests whether university counseling centers (UCC) can apply the concept of cluster analysis, and geospatial analysis to identify clusters of “hot spots”. Participants: Study partici...
1 February 2023 in Seminars in Interventional Radiology
Portomesenteric decompression is often necessary to treat patients with refractory symptoms of portal hypertension. When transjugular or direct intrahepatic portosystemic shunt creation is not feasible or is inadequate, surgical portosystemic shunt creation is considered, which carries significant morbidity and mortality in these high-risk patients. Surgery is further complicated in patients with portomesenteric thrombosis who require concurrent thrombectomy and long-term anticoagulation. In this article, we outline the technique for performing advanced endovascular alternatives to intrahepatic portosystemic shunt creation including mesocaval and splenorenal shunting. We will also discuss some of the clinical considerations for treating these patients with symptomatic portal hypertension and portomesenteric thrombosis. Article published online: 04 May 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
1 October 2026 in Annals of Surgery
Objective: To establish the significance of complete pathologic response (cPR) on survival and locoregional treatment outcomes in a large US cohort. Background: cPR in hepatocellular carcinoma (HCC) is associated with improved post–liver transplant (LT) outcomes. cPR rates, modality-specific differences, and predictors remain undefined. Materials and Methods: Patients were identified from the United Network for Organ Sharing (UNOS) database (2012–2024). cPR was defined as the absence of a viable tumor on explant pathology. Logistic regression identified predictors of cPR, Fine-Gray models estimated the incidence of cPRand Kaplan-Meier analysis assessed survival. Results: Among 7398 LT recipients, 2167 (29.3%) achieved cPR. Imaging–pathology concordance was poor (30.5%), with imaging overestimating response in 42.6% of cases (κ=0.17, P 18 vs. <6 mo; odds ratio (OR): 1.94, 95% CI: 1.57–2.40], Y-90 (41.2%), and ablation (36.4%) were associated with higher cPR rates than transarterial chemoembolization (24.0%; P <0.001). On multivariable analysis, yttrium-90 (Y-90) [adjusted OR (aOR): 1.89, 95% CI: 1.46–2.05] and ablation (aOR: 1.23, 95% CI: 1.08–1.39) independently increased cPR, whereas greater tumor burden and elevated alpha-fetoprotein reduced cPR. Y-90 benefit was greatest when administered ≤6 months of waitlisting (OR: 2.40, 95% CI: 1.59–3.61) and in all-comer candidates (OR: 1.58, 95% CI: 1.17–3.26). Fine-Gray analysis confirmed the highest cumulative incidence of cPR with Y-90 across transplant eligibility criteria. cPR was associated with improved 5-year overall survival (86.6% vs. 77.4%) and recurrence-free survival (76.9% vs. 63.1%; P <0.001). Conclusions: Nearly one-third of LT recipients with HCC achieved cPR, which was associated with improved survival. Y-90 was independently associated with higher cPR rates, particularly when administered early and among patients with higher tumor burden.